KDM5B and non-small cell lung carcinoma: In summary, our study reveals JARID1B-mediated promotion of EMT and CSCs characteristics in NSCLC cells, shows that JARID1B can be a putative marker of tumor progression and poor prognosis in NSCLC patients, and suggests JARID1B may be a good molecular or pharmacological target in NSCLC.